JP2015533822A5 - - Google Patents

Download PDF

Info

Publication number
JP2015533822A5
JP2015533822A5 JP2015534689A JP2015534689A JP2015533822A5 JP 2015533822 A5 JP2015533822 A5 JP 2015533822A5 JP 2015534689 A JP2015534689 A JP 2015534689A JP 2015534689 A JP2015534689 A JP 2015534689A JP 2015533822 A5 JP2015533822 A5 JP 2015533822A5
Authority
JP
Japan
Prior art keywords
pyridin
pyrido
pyrimidin
cyclopropyl
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015534689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533822A (ja
JP6535430B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/062085 external-priority patent/WO2014052699A1/en
Publication of JP2015533822A publication Critical patent/JP2015533822A/ja
Publication of JP2015533822A5 publication Critical patent/JP2015533822A5/ja
Application granted granted Critical
Publication of JP6535430B2 publication Critical patent/JP6535430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015534689A 2012-09-28 2013-09-27 非定型プロテインキナーゼcのアザキナゾリン阻害薬 Active JP6535430B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261707340P 2012-09-28 2012-09-28
US61/707,340 2012-09-28
US201361781364P 2013-03-14 2013-03-14
US61/781,364 2013-03-14
PCT/US2013/062085 WO2014052699A1 (en) 2012-09-28 2013-09-27 Azaquinazoline inhibitors of atypical protein kinase c

Publications (3)

Publication Number Publication Date
JP2015533822A JP2015533822A (ja) 2015-11-26
JP2015533822A5 true JP2015533822A5 (enExample) 2017-06-22
JP6535430B2 JP6535430B2 (ja) 2019-06-26

Family

ID=49326872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015534689A Active JP6535430B2 (ja) 2012-09-28 2013-09-27 非定型プロテインキナーゼcのアザキナゾリン阻害薬

Country Status (18)

Country Link
US (2) US9914730B2 (enExample)
EP (1) EP2900666B1 (enExample)
JP (1) JP6535430B2 (enExample)
KR (1) KR102215272B1 (enExample)
CN (1) CN105102456B (enExample)
AU (1) AU2013323360B2 (enExample)
BR (1) BR112015007061B1 (enExample)
CA (1) CA2886495C (enExample)
CL (1) CL2015000781A1 (enExample)
EA (1) EA030253B1 (enExample)
IL (1) IL237918B (enExample)
MX (1) MX372736B (enExample)
NZ (1) NZ706857A (enExample)
PH (1) PH12015500689A1 (enExample)
SG (1) SG11201502301YA (enExample)
TW (1) TWI663165B (enExample)
WO (1) WO2014052699A1 (enExample)
ZA (1) ZA201502783B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX372736B (es) * 2012-09-28 2020-06-19 Cancer Research Tech Ltd Inhibidores de azaquinazolina de la proteina quinasa c atipica.
JP6391120B2 (ja) 2012-12-20 2018-09-19 サンフォード−バーンハム メディカル リサーチ インスティテュート ニューロテンシン受容体1の小分子アゴニスト
GEP201706780B (en) 2013-03-14 2017-11-27 Boehringer Ingelheim Int Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
NZ718190A (en) 2013-08-23 2017-10-27 Neupharma Inc Substituted quinazolines for inhibiting kinase activity
WO2015143376A1 (en) * 2014-03-21 2015-09-24 Nivalis Therapeutics, Inc. Novel compounds for the treatment of cystic fibrosis
TWI675836B (zh) * 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶c之氮雜喹唑啉抑制劑
WO2015200534A2 (en) 2014-06-25 2015-12-30 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
WO2016004272A1 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016037106A1 (en) * 2014-09-05 2016-03-10 Allosteros Therapeutics, Inc CaMKII INHIBITORS AND USES THEREOF
UA118610C2 (uk) 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
SG11201702075QA (en) * 2014-10-29 2017-04-27 Dong A St Co Ltd Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
CN105288512A (zh) * 2015-12-08 2016-02-03 李野林 一种治疗肥胖症的中药组合物
ES2993451T3 (en) 2016-06-13 2024-12-30 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
AU2017312561B2 (en) * 2016-08-15 2022-06-30 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2017312970B2 (en) * 2016-08-16 2021-08-12 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof
WO2018051306A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
JOP20190257A1 (ar) * 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
KR20240032157A (ko) 2017-05-02 2024-03-08 노파르티스 아게 병용 요법
KR102563325B1 (ko) 2017-06-30 2023-08-03 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Rho-관련 단백질 키나아제 억제제, Rho-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
WO2019001572A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
KR102603203B1 (ko) 2018-07-25 2023-11-16 파에스 파마, 에스.에이. 히스타민 h4-수용체 저해제로서 피리도피리미딘류
EP3831823A4 (en) * 2018-08-01 2022-04-27 Shanghai Ennovabio Pharmaceuticals Co., Ltd. PREPARATION AND USE OF AN AROMATIC COMPOUND WITH IMMUNEGULATORY FUNCTION
CN111100063B (zh) * 2018-10-25 2022-05-17 南京药石科技股份有限公司 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法
JP7603605B2 (ja) * 2019-03-28 2024-12-20 キャンサー・リサーチ・テクノロジー・リミテッド 非定型プロテインキナーゼcの阻害剤およびヘッジホッグ経路依存性癌の治療におけるその使用
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
CN116120243B (zh) * 2021-11-15 2025-07-29 都创(上海)医药科技股份有限公司 aPKC抑制剂化合物中间体片段及其制备方法和应用
CN114349711B (zh) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 一种(R)-1-Boc-3-羟甲基哌嗪的合成方法
CN117088898B (zh) * 2022-05-13 2026-02-06 中国药科大学 稠环嘧啶类化合物及其制备方法、药物组合物和应用
CN120882714A (zh) * 2022-12-13 2025-10-31 风树疗法公司 {5-环丙基-2-[2-(3,6-二氟-吡啶-2-基氨基)-吡啶-4-基]-吡啶并[3,4-d]嘧啶-4-基}-((s)-3,3-二甲基-哌啶-4-基)-胺的固体形式
CN117343005A (zh) * 2023-10-08 2024-01-05 上海泰坦科技股份有限公司 一种异烟酸衍生物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4936700A (enExample) 1972-08-16 1974-04-05
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP2002080423A (ja) * 2000-09-06 2002-03-19 Daikin Ind Ltd トリフルオロ酢酸エチルの合成方法
DK1318997T3 (da) * 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4895806B2 (ja) * 2003-04-09 2012-03-14 エクセリクシス, インク. Tie−2モジュレータと使用方法
US20050038047A1 (en) * 2003-08-14 2005-02-17 Edwards Paul John Azaquinazoline derivatives
US7582631B2 (en) * 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2008531538A (ja) * 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 2,4−ジアミノ−ピリドピリミジン誘導体とmTOR阻害剤としてのその使用
AU2007287430B2 (en) * 2006-08-23 2011-07-21 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
RU2009108006A (ru) * 2006-09-08 2010-10-20 Пфайзер Продактс Инк. (Us) Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов
US8993552B2 (en) * 2009-09-04 2015-03-31 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
MX372736B (es) * 2012-09-28 2020-06-19 Cancer Research Tech Ltd Inhibidores de azaquinazolina de la proteina quinasa c atipica.
WO2014164543A1 (en) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016040330A1 (en) * 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
KR20180103053A (ko) * 2015-12-22 2018-09-18 비타이 파마슈티컬즈, 인코포레이티드 메닌-mll 상호작용의 억제제

Similar Documents

Publication Publication Date Title
JP2015533822A5 (enExample)
AU2013323360B2 (en) Azaquinazoline inhibitors of atypical protein kinase C
JP6545863B2 (ja) Fgfr阻害剤としての置換三環式化合物
WO2024107686A1 (en) Macrocyclic kras inhibitors and methods of use
EP2558468B1 (en) 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
CN117651700A (zh) 2-氨基苯并噻唑化合物及使用方法
KR101812357B1 (ko) Cdk4/6의 억제제로서의 피롤로피리미딘 화합물
EP3768668A1 (en) Shp2 phosphatase inhibitors and methods of use thereof
JP2017518326A5 (enExample)
HRP20160649T1 (hr) Novi derivati tienopirimidina, postupci za njihovo pripremanje i njihova terapeutska uporaba
JP2015521600A5 (enExample)
CA2687035A1 (en) Amino-heterocyclic compounds
HRP20151442T1 (hr) Spojevi heteroaril piridona i aza-piridona kao inhibitori btk-djelovanja
JP2011511034A5 (enExample)
JP2015537010A5 (enExample)
RU2015122895A (ru) Пуриновые ингибиторы человеческой фосфатидилинозит 3-киназы дельта
JP2017505327A5 (enExample)
JP2015504057A5 (enExample)
KR20120102724A (ko) 신규한 트리사이클릭 화합물
JP2021504380A5 (enExample)
JPWO2019156987A5 (enExample)
WO2025230862A1 (en) Macrocyclic amino compounds as modulators of kras and uses therof
WO2025230878A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
WO2025194057A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
CN117897159A (zh) 杂环化合物及使用方法